The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Questcor Pharmaceuticals to Present at the Citigroup Global Health Care Conference on February 27, 2012

Thursday, February 23, 2012

Questcor Pharmaceuticals to Present at the Citigroup Global Health Care Conference on February 27, 201206:30 EST Thursday, February 23, 2012ANAHEIM, Calif., Feb. 23, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the Citigroup Global Health Care Conference to be held on February 27-29, 2012 in New York.  Don M. Bailey, President and Chief Executive Officer, is scheduled to present an overview of the Company on Monday, February 27, 2012 at 9:30 a.m. ET.A live webcast and subsequent archived replay of the presentation will be accessible at  The replay will be available for 90 days after the event.About Questcor                                                                                      Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Questcor currently generates substantially all of its net sales from: the treatment of patients with acute exacerbations of multiple sclerosis in adults, the treatment of patients with nephrotic syndrome, and the treatment of patients with infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also currently planning to explore the potential initiation of a commercial effort in rheumatology, as Acthar is approved for several rheumatology-related conditions including Lupus, and Dermatomyositis (Polymyositis).  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  In October 2011, Forbes magazine ranked Questcor number one in its annual rankings of America's Best Small Companies.  For more information about Questcor, please visit   SOURCE Questcor Pharmaceuticals, Inc.For further information: Questcor Pharmaceuticals, Inc., Don Bailey, +1-714-786-4210,; or EVC Group, Investors, Gregory Gin +1-646-445-4801, or Doug Sherk, +1-415-568-4887, or Media, Janine McCargo, 646-688-0425